Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Michelle Lazenby"'
Autor:
Christoph Hieber, Al-Hassan M. Mustafa, Sarah Neuroth, Sven Henninger, Hans-Peter Wollscheid, Joanna Zabkiewicz, Michelle Lazenby, Caroline Alvares, Siavosh Mahboobi, Falk Butter, Walburgis Brenner, Matthias Bros, Oliver H. Krämer
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 177, Iss , Pp 117076- (2024)
Hyperactive FMS-like receptor tyrosine kinase-3 mutants with internal tandem duplications (FLT3-ITD) are frequent driver mutations of aggressive acute myeloid leukemia (AML). Inhibitors of FLT3 produce promising results in rationally designed cotreat
Externí odkaz:
https://doaj.org/article/92a388417b2242c48063d7ece8629a1e
Autor:
Joanna Zabkiewicz, Nader Omidvar, Alan Kenneth Burnett, Carol Guy, Steve Knapper, Michelle Lazenby, Robert Kerrin Hills, Gareth Edwards, Lihui Zhuang, Ceri Bygrave, Caroline Alvares
Publikováno v:
British journal of haematologyReferences. 191(2)
Minimal residual disease (MRD) in acute myeloid leukaemia (AML) poses a major challenge due to drug insensitivity and high risk of relapse. Intensification of chemotherapy and stem cell transplantation are often pivoted on MRD status. Relapse rates a
Autor:
Fabiana Ostronoff, Min Fang, Jerald P. Radich, Soheil Meshinchi, Stephen H. Petersdorf, Michelle Lazenby, Alan F. List, Alan Kenneth Burnett, Elihu H. Estey, Cheryl L. Willman, Anna Evans, Era L. Pogosova-Agadjanyan, John E. Godwin, Frederick R. Appelbaum, Kenneth J. Kopecky, Vivian G. Oehler, Megan Othus, Derek L. Stirewalt, Amanda F. Gilkes
Publikováno v:
Journal of Clinical Oncology. 33:1157-1164
Purpose Younger patients with acute myeloid leukemia (AML) harboring NPM1 mutations without FLT3–internal tandem duplications (ITDs; NPM1-positive/FLT3-ITD–negative genotype) are classified as better risk; however, it remains uncertain whether th
Publikováno v:
Blood. 132:2744-2744
Background Haematopoietic stem cell transplantation is still the most effective anti-leukaemic therapy for AML treatment for a large number of patients, but a significant proportion of these will relapse post-transplant and the probability of long te
Publikováno v:
Leukemia. 25:411-419
SNS-032 (BMS-387032) is a selective cyclin-dependent kinase (CDK) inhibitor. In this study, we evaluated its effects on primary acute myeloid leukemia (AML) samples (n=87). In vitro exposure to SNS-032 for 48 h resulted in a mean LD(50) of 139±203 n
Autor:
Peli Foka, Beatrice Malgesini, Ilario Verpilio, Paolo Ferruti, Ruth Duncan, Nathalie Lavignac, Michelle Lazenby
Publikováno v:
Macromolecular Bioscience. 4:922-929
The poly(amidoamine)s (PAAs) ISA 1 and ISA 23 display pH-dependent conformational change and pH-dependent membrane perturbation. These properties confer potential for use as endosomolytic polymers for intracytoplasmic delivery of toxins and genes. Bo
Autor:
Anna Evans, Amanda F. Gilkes, Robert Kerrin Hills, C. Marrin, Alan Kenneth Burnett, Michelle Lazenby
Publikováno v:
Leukemia. 28(10)
Although the prognostic impact of mutations of FLT3 and NPM1 have been extensively studied in younger patients with acute myeloid leukaemia, less is known in older patients whether treated intensively or non-intensively, or in the context of existing
Publikováno v:
British journal of haematology. 161(1)
Heat shock protein 90 (HSP90; HSP90AA1) is a molecular chaperone involved in signalling pathways for cell proliferation, survival, and cellular adaptation. Inhibitors of HSP90 are being examined as anti-cancer agents, but the critical molecular mecha
Publikováno v:
International journal of pharmaceutics. 300(1-2)
The pH-responsive poly(amidoamine)s (PAAs) have been previously described. Whereas ISA23 enhances transfection in vitro and ISA1 promotes the cytosolic delivery of the non-permeant toxins this process shows poor efficiency. The aim of this study was
Autor:
Ann Hunter, Michelle Lazenby, Amanda F. Gilkes, Lone S. Friis, Lars Kjeldsen, Alan Kenneth Burnett, Robert Kerrin Hills, David G. Bowen, Donald Milligan, Nigel H. Russell
Publikováno v:
Blood. 122:493-493
Background There is conflicting data on the effect of the addition of ATRA to chemotherapy in AML. Two large randomised trials showed no benefit (Estey et al Blood 1999; 93, 2478 (n=215); Burnett et al. Blood 2010, 115: 9482 (n=1075)), or benefit whi